Who Paid My Doc
Spinraza
Biological Neurology
NDC 64406-058-01
General payments
$6,486,462
Research payments
$47,010,237
Through program year 2025, $6,486,462 in general payments and $47,010,237 in research payments were reported against Spinraza (Neurology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
14 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $314,293 | 1,847 |
| 2025 | Research | $3,292,371 | 65 |
| 2024 | General | $575,536 | 2,043 |
| 2024 | Research | $9,646,326 | 73 |
| 2023 | General | $663,394 | 2,851 |
| 2023 | Research | $7,402,662 | 74 |
| 2022 | General | $984,890 | 2,435 |
| 2022 | Research | $10,552,362 | 69 |
| 2021 | General | $722,680 | 1,988 |
| 2021 | Research | $5,776,791 | 60 |
| 2020 | General | $660,110 | 1,117 |
| 2020 | Research | $5,744,844 | 44 |
| 2019 | General | $2,565,558 | 3,960 |
| 2019 | Research | $4,594,881 | 58 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 74 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 48 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
16,241 general · 443 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.